Potential use of lactic acid in obstetrics and gynecology
DOI: 10.32364/2618-8430-2022-5-2-138-145
A.M. Savicheva1,2, P.A. Shadrova3
1D.O. Ott Research Institute of Obstetrics, Gynecology, & Reproduction, St. Petersburg,
Russian Federation
2St. Petersburg State Pediatric Medical University, St. Petersburg, Russian Federation
3Pirogov Russian National Research Medical University, Moscow, Russian Federation
Inflammatory diseases and dysbiosis provoked by opportunistic microbes currently rank first among lower reproductive tract infections in women. Lactobacilli are predominant in the vaginal microecosystem that is considered the first line of defense against infectious agents. Changes in hormonal profile, the pattern of intimate hygiene and sex life, and other factors impair the vaginal microecosystem. Diseases resulting from the activation of aerobic and anaerobic opportunistic microbes are particularly harmful during pregnancy, since they cause serious reproductive disorders and significantly increase the risks of perinatal complications. Frequent recurrences due to growing antibiotic resistance and the lack of potential antimicrobial treatment in the first trimester of pregnancy force to search for alternative therapeutic tools with good efficacy and safety. Topical agents containing lactic acid decrease vaginal pH and provide unfavorable conditions for the activity o f opportunistic microbes, thereby maintaining the protective functions of Lactobacilli. Lactic acid is a natural chemical for this locus. As a result, agents containing this compound are virtually lacking side effects. They can be used along with antibiotics or as monotherapy.
Keywords: bacterial vaginosis, aerobic vaginitis, lactic acid, opportunistic microbes, vaginal microbiota, Lactobacilli, dysbiosis, pregnancy, normal flora.
For citation: Savicheva A.M., Shadrova P.A. Potential use of lactic acid in obstetrics and gynecology. Russian Journal of Woman and Child Health. 2022;5(2):138–145 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-138-145.
About the authors:
Alevtina M. Savicheva — Dr. Sc. (Med.), Professor, Head of the Division of Medical Microbiology, Head of the Laboratory of Clinical Microbiology, D.O. Ott Research Institute of Obstetrics, Gynecology, & Reproduction; 3, Mendeleevskaya line, St. Petersburg, 199034, Russian Federation; Head of the Department of Clinical Lab Diagnostics, St. Petersburg State Pediatric Medical University; 2, Litovskaya str., St. Petersburg, 194100, Russian Federation; ORCID iD 0000-0003-3870-5930.
Polina A. Shadrova — postgraduate student of the Department of Obstetrics and Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; ORCID iD 0000-0002-3721-1421.
Contact information: Polina A. Shadrova, e-mail: shadrovapolina@hotmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 17.03.2022.
Revised 11.04.2022.
Accepted 28.04.2022.
2. Wagenlehner F., Wullt B., Ballarini S. et al. Social and economic burden of recurrent urinary tract infections and quality of life: a patient webbased study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res. 2018;18(1):107–117. DOI: 10.1080/14737167.2017.135954.
3. Stapleton A.E. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr. 2016;4(6):10.1128/microbiolspec.UTI-0025–2016. DOI: 10.1128/microbiolspec.UTI-0025-2016.
4. Lewis A.L., Gilbert N.M. Roles of the vagina and the vaginal microbiota in urinary tract infection: evidence from clinical correlations and experimental models. GMS Infect Dis. 2020;8:02. DOI: 10.3205/id000046.
5. Sherrard J., Wilson G., Donders J. et al. European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29:1258–1272. DOI: 10.1177/0956462418785451.
6. Donders G. Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv. 2010;65:462–473. DOI: 10.1097/OGX.0b013e3181e09621.
7. Alves P., Castro J., Sousa C. et al. Gardnerella vaginalis outcompetes 29 other bacterial species isolated from patients with bacterial vaginosis, using in an in vitro biofilm formation model. J Infect Dis. 2014;210(4):593–596. DOI: 10.1093/infdis/jiu131.
8. Swidsinski A., Mendling W., Loening-Baucke V. et al. Adherent biofilms in bacterial vaginosis. Obstet Gynecol. 2005;106:1013–1023. DOI: 10.1097/01.AOG.0000183594.45524.d2.
9. Vaneechoutte M., Guschin A., van Simaey L. et al. Emended description of Gardnerella vaginalis and description of Gardnerella leopoldii sp. nov., Gardnerella piotii sp. nov. and Gardnerella swidsinskii sp. nov., with delineation of 13 genomic species within the genus Gardnerella. Int J Syst Evol Microbiol. 2019;69(3):679–687. DOI: 10.1099/ijsem.0.003200.
10. Hillier S.L., Marrazzo J., Holmes K.K. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill; 2008.
11. Muzny C.A., Taylor C.M., Swords W.E. et al. An Updated Conceptual Model on the Pathogenesis of Bacterial Vaginosis. J Infect Dis. 2019;220(9):1399–1405. DOI: 10.1093/infdis/jiz342.
12. Mitchell C., Marrazzo J. Bacterial vaginosis and the cervicovaginal immune response. Am J Reprod Immunol. 2014;71(6):555–563. DOI: 10.1111/aji.12264.
13. Swidsinski A., Mendling W., Loening‐Baucke V. et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97.e1–6. DOI: 10,1016/j.ajog.2007.06.039.
14. Gonçalves C.S., Morton A.N., Hocking J. et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193:1478. DOI: 10.1086/503780.
15. Krysanova A.A., Gushchin A.E., Savicheva A.M. Significance of Gardnerella vaginalis genotyping in the diagnosis of recurrent bacterial vaginosis. Medical alphabet. 2021;30:48–52 (in Russ.). DOI: 10.33667/2078- 5631-2021-30-48-52.
16. Menukhova Yu.N. Evaluation of clinical and microbiological criteria for the diagnosis and effectiveness of treatment of bacterial vaginosis: thesis. St. Petersburg; 2014 (in Russ.).
17. Van Oostrum N., de Sutter P., Meys J., Verstraelen H. Risks associated with bacterial vaginosis in infertility patients: a systematic review and meta-analysis. Hum Reprod. 2013;28(7):1809–1815. DOI: 10.1093/humrep/ det096.
18. Taylor-Robinson D., Boustouller Y.L. Damage to oviduct organ cultures by Gardnerella vaginalis. Int J Exp Pathol. 2011;92(4):260–265. DOI: 10.1111/j.1365-2613.2011.00768.x.
19. Swidsinski A., Verstraelen H., Loening-Baucke V. et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One. 2013;8(1):e53997. DOI: 10.1371/journal.pone.0053997.
20. Subtil D., Brabant G., Tilloy E. et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Lancet. 2018;392(10160):2171–2179. DOI: 10.1016/S0140-6736(18)31617-9.
21. Abou C.L., Fenollar F., Diop K. Bacterial Vaginosis: What Do We Currently Know? Front Cell Infect Microbiol. 2022;11:672429. DOI: 10.3389/fcimb.2021.672429.
22. Grodnitskaya E.E., Shamanova M.B., Paley O.S., Kurtser M.A. Microbiocenosis of the vagina and ways of its correction in women with a history of spontaneous abortion in late gestation. Russian Bulletin of an obstetrician-gynecologist. 2011;1:21–25 (in Russ.).
23. Donders G.G., Bosmans E., Dekeersmaecker A. et al. Pathogenesis of Abnormal Vaginal Bacterial Flora. Am J Obstet Gynecol. 2020;182(4):872–878. DOI: 10.1016/s0002-9378(00)70338-3.
24. Rumyantseva T.A., Bellen G., Savochkina Y.A. et al. Diagnosis of Aerobic Vaginitis by Quantitative Real-Time PCR. Arch Gynecol Obstet. 2016;294(1):109–114. DOI: 10.1007/s00404-015-4007-4.
25. Dermendjiev T., Pehlivanov B., Hadjieva K., Stanev S. Epidemiological, clinical and microbiological findings in women with aerobic vaginitis. Akush Ginekol (Sofiia). 2015;54(9):4–8.
26. Donders G., Bellen G., Grinceviciene S. et al. Aerobic vaginitis: no longer a stranger. Res Microbiol. 2017;168(9–10):845–858. DOI: 10.1016/j. resmic.2017.04.004.
27. Hedges S.R., Barrientes F., Desmond R.A., Schwebke J.R. Local and systemic cytokine levels in relation to changes in vaginal flora. J Infect Dis. 2006;193:556–562. DOI: 10.1086/499824.
28. Budilovskaya O.V., Shipitsyna E.V., Thanksgiving E.V. et al. Differential expression of local immune response genes in the vagina: implications for the diagnosis of vaginal infections. Bulletin of experimental biology and medicine. 2019;168(11):588–592 (in Russ.).
29. Lewis W.G., Robinson L.S., Perry J.C. et al. Hydrolysis of the secreted sialoglycoprotein Immunoglobulin A (IgA) in ex vivo and biochemical models of bacterial vaginosis. J Biological Chemistry. 2012;287:2079–2089. DOI: 10.1074/jbc.M111.278135.
30. Prilepskaya V.N., Kira E.F., Apolikhina I.A. Clinical recommendations for the diagnosis and treatment of diseases accompanied by pathological discharge from the genital tract of women: manual. M.; 2019 (in Russ.).
31. Cauci S., Culhane J.F., Di S.M., McCollum K. Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta. Am J Obstet Gynecol. 2008;198:132–137. DOI: 10.1016/j.ajog.2007.05.035.
32. Hassan M.F., Rund N.M.A., El-Tohamy O. et al. Does Aerobic Vaginitis Have Adverse Pregnancy Outcomes? Prospective Observational Study. Infect Dis Obstet Gynecol. 2020;2020:5842150. DOI: 10.1155/2020/5842150.
33. Ravel J., Gajer P., Abdo Z. et al. Vaginal microbiome of reproductive age women. Proc Natl Acad Sci USA. 2011;108(Suppl 1):4680–4687. DOI: 10.1073/pnas.1002611107.
34. Valenti P., Rosa L., Capobianco D. et al. Role of Lactobacilli and Lactoferrinin the Mucosal Cervicovaginal Defense. Front Immunol. 2018;9:376. DOI: 10.3389/fimmu.2018.00376.
35. Savicheva A.M., Tapilskaya N.I., Shipitsyna E.V. Bacterial vaginosis and aerobic vaginitis as the main disturbances in the balance of the vaginal microflora. Features of diagnostics and therapy. Obstetrics and gynecology. 2017;5:24–31 (in Russ.). DOI: 10.18565/aig.2017.5.24-31.
36. Amabebe E., Anumba D.O.C. The vaginal microenvironment: the physiologic role of Lactobacilli. Front Med (Lausanne). 2018;5:181. DOI: 10.3389/fmed.2018.00181.
37. Sinyakova A.A., Shipitsyna E.V., Budilovskaya O.V. Peculiarities of the vaginal microflora in the first trimester in women with a history of miscarriage. Journal of Obstetrics and Women’s Diseases. 2018;67(5):32–41 (in Russ.). DOI: 10.17816/JOWD67532-41.
38. Kafarskaya L.I., Efimov B.A., Artemova L.V. and other Microecology of the vagina. Microbiocenosis in normal conditions, in pathological conditions and methods for its correction. Lecture. M.; 2005 (in Russ.).
39. Edwards V.L., Smith S.B., McComb E.J. et al. The cervicovaginal microbiota host interaction modulates Chlamydia trachomatis infection. Med Bio. 2019;10(4):e01548. DOI: 10.1128/mBio.01548-19.
40. Kira E.F. Bacterial vaginosis. M.: "Medical Information Agency"; 2012 (in Russ.).
41. O’Hanlon D.E., Moench T.R., Cone R.A. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis. 2011;11:200. DOI: 10.1186/1471-2334-11-200.
42. Tachedjian G., Aldunate M., Bradshaw C.S. et al. The role of lactic acid production by probiotic Lactobacillus species in vaginal health. Res Microbiol. 2017;168(9–10):782–792. DOI: 10.1016/j.resmic.2017.04.001.
43. Lourenço A., Pedro N.A., Salazar S.B. Effect of Acetic Acid and Lactic Acid at Low pH in Growth and Azole Resistance of Candida albicans and Candida glabrata. Front Microbiol. 2018;9:3265. DOI: 10.3389/ fmicb.2018.03265.
44. Clinical recommendations. Bacterial vaginosis. M.; 2022 (in Russ.).
45. Clinical recommendations. Diagnosis and treatment of diseases accompanied by pathological discharge from the genital tract of women. M.; 2019 (in Russ.).
46. Conti C., Malacrino C., Mastromarino P. Inhibition of herpes simplex virus type 2 by vaginal lactobacilli. J Physiol Pharmacol. 2009;60(6):19–26.
47. Sherrard J., Wilson J., Donders G. et al. 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018;29(13):1258–1272. DOI: 10.1177/0956462418785451.
48. Kira E.F., Rybalchenko O.V., Orlova O.G., Korshakova N.Yu. Study of lactic acid activity in vitro and its significance for clinical practice in the treatment of vaginal infections. Obstetrics and gynecology. 2017;11:84–90. (in Russ.). DOI: 10.18565/aig.2017.11.84-91.
49. Kira E.F., Pekarev O.G., Molchanov O.L. Comparative analysis of the efficacy and safety of parallel or sequential combination of metronidazole with lactic acid and a two-stage method of metronidazole plus a probiotic. Multicenter randomized controlled trial. Obstetrics and gynecology. 2016;9:87–93 (in Russ.). DOI: 10.18565/aig.2016.9.87-93.
50. Kira E.F., Prilepskaya V.N., Kostava M.N. et al. Modern approaches to the choice drug of local action in the treatment of bacterial vaginosis. Obstetrics and gynecology. 2012;7:59–67 (in Russ.).
51. Instructions for the medical use of the drug Lactodepantol (Electronic resource.) URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=87d480af-fe1a-459e-a995-41e039221be9&t= (access date: 11.02.2022) (in Russ.).
52. Radzinsky V.E., Khamoshina M.B., Orazov M.R. et al. Results of a multicenter observational study: treatment of acute vaginitis of nonspecific and mixed etiology in patients of reproductive age. Obstetrics and gynecology. 2019;8:150–158 (in Russ.). DOI: 10.18565/aig.2019.8.150-158.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
